EU Regulators Recommend Xolair for Hives
Disclosures January 24, 2014
Drug regulators in the European Union (EU) have recommended approving omalizumab ( Xolair, Novartis, Genentech) as an add-on therapy for patients with chronic spontaneous urticaria (CSU), the European Medicines Agency (EMA) announced today.
Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study
D'Erme AM, Zanieri F, Campolmi E, Santosuosso U, Betti S, Agnoletti AF, Cossidente A, Lotti T; Journal of the European Academy of Dermatology and Venereology (Sep 2012)
Source: J Eur Acad Dermatol Venereol